New model aims to predict breast cancer recurrence years after treatment
NCT ID NCT07484763
First seen Apr 03, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study looks back at 500 women with a common type of early breast cancer (HR+/HER2-) to create a personalized risk calculator. The goal is to better predict who might have a recurrence years later, helping doctors decide on extra treatments. No new drugs are tested; instead, the team uses existing patient data to improve decision-making.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, HR+/HER2- EARLY-STAGE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.